Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, B-Cell 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 12Recurrence 11Burkitt Lymphoma 10Multiple Myeloma 7Lymphoma 7Neoplasms 6Leukemia, Myeloid, Acute 6Lymphoma, Mantle-Cell 5Leukemia 5Pancreatic Neoplasms 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Leukemia, B-Cell 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Simpson-Golabi-Behmel syndrome 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2

Interventions

Cyclophosphamide 117Rituximab 115fludarabine phosphate 79Peripheral Blood Stem Cell Transplantation 71Mycophenolic Acid 55Whole-Body Irradiation 52Filgrastim 49Tacrolimus 43Cyclosporine 43Radiotherapy 41Busulfan 41Antilymphocyte Serum 38Etoposide 36Melphalan 34Lenalidomide 31Methotrexate 25fludarabine 23Cord Blood Stem Cell Transplantation 22Bortezomib 20Flow Cytometry 19Cytarabine 19Methylprednisolone 18Bendamustine Hydrochloride 18obinutuzumab 17Prednisone 15Granulocyte Colony-Stimulating Factor 15Carmustine 15sargramostim 14orelabrutinib 14Therapeutics 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell, Marginal Zone × Immunotherapy, Adoptive × Clear all
NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Fred Hutchinson Cancer Center

Phase 1/2 Active not recruiting
53 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡